Sen. Ron Wyden says he has "a number of concerns" about how panelists were selected and screened for an advisory panel on pain issues that includes government experts, outside academics and patient advocates.
There might be another tool in the battle against high drug costs: state consumer protection laws. A potential lawsuit in Massachusetts against drugmaker Gilead over its costly hepatitis C drugs could, if successful, forge a new path for states working to combat the high costs of certain drugs.
Ann Arbor, Mich.-based Millendo Therapeutics announced Tuesday morning it has raised a venture capital round of $62 million, the largest VC round for a drug development company in Michigan history.
Pharmaceutical giants Pfizer and Allergan are reportedly nearing a blockbuster deal that could be announced as soon as this week.
An expected deal between pharmaceutical giants Pfizer and Allergan that's expected to be worth up to $380 a share could become less lucrative under new U.S. Treasury rules designed to diminish the benefits of cross-border transactions.
Providers and insurers need to do a better job of reaching patients and employers to help private accountable care organizations achieve lower costs and higher quality, according to physician executives at four large health insurance companies.
Drug giant AstraZeneca was denied approval of a diabetes drug combination treatment by U.S. regulators, citing the need for more clinical information.
Genentech, the maker of Avastin and other pricey cancer drugs, paid physicians and teaching hospitals more than any other drug or device company did in 2014, according to data published last week on the CMS' Open Payments website.
The federal government is launching a very different kind of cancer study that will assign patients drugs based on what genes drive their tumors rather than the type.
Medicare shelled out more than $103 billion on prescription drugs in 2013, raising questions about why the government pays so much for brand-name pharmaceuticals and how physicians prescribe drugs for their patients.
Merck & Co. said preliminary results of a post-market study of its diabetes drug Januvia showed no increase in hospitalization compared with patients who did not use the drug.
Lawyers say the suit against AstraZeneca and Ranbaxy has yielded the first jury decision in a so-called pay-for-delay case since a U.S. Supreme Court decision made it easier to challenge such agreements under federal antitrust law.